Study Summary
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T lymphocytes (CTLs) and immune-modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negative in B-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.
Want to learn more about this trial?
Request More InfoInterventions
Antigen-specific T cells CART/CTL and DCvacBIOLOGICAL
Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Shenzhen | Guangdong | China |